---
title: "Otezla (apremilast), all indications: Safety questions"
description: "Safety questions on Otezla (apremilast) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Warnings. Questions: Can Otezla cause severe diarrhea, nausea, or vomiting? Can Otezla cause depression or suicidal thoughts? Who should not take Otezla (contraindications)? Can Otezla cause allergic reactions? 4 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/otezla/safety"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Otezla (apremilast), all indications: Safety questions

Manufacturer: Amgen Inc.  
Prescribing information: [Otezla](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf)  
Indication pages: [Plaque psoriasis](https://www.evicenter.com/medical-information/otezla--plaque-psoriasis)

## Warnings

<a id="otezla-diarrhea-nausea-vomiting"></a>

### Can Otezla cause severe diarrhea, nausea, or vomiting?

> “There have been reports of severe diarrhea, nausea, and vomiting associated with the use of OTEZLA. 
> Most events occurred within the first few weeks of treatment. In some cases, patients were hospitalized. 
> Patients 65 years of age or older and patients taking medications that can lead to volume depletion or 
> hypotension may be at a higher risk of complications from severe diarrhea, nausea, or vomiting. Monitor 
> patients who are more susceptible to complications of diarrhea or vomiting. Patients who reduced dosage 
> or discontinued OTEZLA generally improved quickly. Consider OTEZLA/OTEZLA XR dosage 
> reduction or suspension if patients develop severe diarrhea, nausea, or vomiting.”

Source: [OTEZLA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=6)

> “The most common adverse reactions leading to discontinuation for subjects taking 
> OTEZLA were nausea (1.6%), diarrhea (1.0%), and headache (0.8%).”

Source: [OTEZLA: Prescribing information, page 10, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=10)

Note: The second passage concerns the adult moderate to severe plaque psoriasis trials.

<a id="otezla-depression"></a>

### Can Otezla cause depression or suicidal thoughts?

> “Treatment with apremilast is associated with an increased incidence of depression. Before using 
> OTEZLA/OTEZLA XR in patients with a history of depression and/or suicidal thoughts or behavior, 
> carefully weigh the risks and benefits of treatment with OTEZLA/OTEZLA XR. Advise patients, their 
> caregivers, and families of the need to be alert for the emergence or worsening of depression, suicidal 
> thoughts or other mood changes, and if such changes occur to contact their healthcare provider. Carefully 
> evaluate the risks and benefits of continuing treatment with OTEZLA/OTEZLA XR if such events occur.”

Source: [OTEZLA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=6)

> “Plaque Psoriasis: During the 16-week placebo-controlled period of the 3 controlled clinical trials in adult 
> subjects with moderate to severe plaque psoriasis, 1.3% (12/920) of subjects treated with OTEZLA 
> reported depression compared to 0.4% (2/506) treated with placebo. During the clinical trials, 0.1% 
> (1/1308) of subjects treated with OTEZLA discontinued treatment due to depression compared with none 
> in placebo-treated subjects (0/506). Depression was reported as serious in 0.1% (1/1308) of subjects 
> exposed to OTEZLA, compared to none in placebo-treated subjects (0/506). Instances of suicidal 
> behavior have been observed in 0.1% (1/1308) of subjects while receiving OTEZLA, compared to 0.2% 
> (1/506) in placebo-treated subjects. In the clinical trials, one subject treated with OTEZLA attempted 
> suicide while one who received placebo committed suicide.”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

> “During the 16-week placebo-controlled period of the clinical trial in adults with mild to moderate plaque 
> psoriasis, the incidence of subjects reporting depression was similar to what was observed in the adult 
> moderate to severe plaque psoriasis trials.”

Source: [OTEZLA: Prescribing information, page 7, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=7)

<a id="otezla-contraindications"></a>

### Who should not take Otezla (contraindications)?

> “OTEZLA/OTEZLA XR is contraindicated in patients with a known hypersensitivity to apremilast or to 
> any of the excipients in the formulation [see Warnings and Precautions (5.1), see Adverse Reactions 
> (6.1)].”

Source: [OTEZLA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=6)

<a id="otezla-allergic-reactions"></a>

### Can Otezla cause allergic reactions?

> “Hypersensitivity reactions, including cases of angioedema and anaphylaxis, have been reported during 
> post marketing surveillance. Avoid the use of OTEZLA/OTEZLA XR in patients with known 
> hypersensitivity to apremilast or to any of the excipients in the formulation. If signs or symptoms of 
> serious hypersensitivity reactions develop during treatment, discontinue OTEZLA/OTEZLA XR and 
> institute appropriate therapy.”

Source: [OTEZLA: Prescribing information, page 6, captured 2026-11-13](https://www.pi.amgen.com/united_states/otezla/otezla_pi_english.pdf#page=6)

## Related pages
- [Medical information: Otezla (apremilast): All indications](https://www.evicenter.com/medical-information/otezla)
- [Indication](https://www.evicenter.com/medical-information/otezla/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/otezla/pharmacology)
- [Specific populations](https://www.evicenter.com/medical-information/otezla/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/otezla/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/otezla/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/otezla/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/otezla/access-and-coverage)
